Two Scottish holding companies that own 22 community pharmacies have been placed into administration, yet the pharmacies themselves remain operational as administrators seek to sell them as going concerns. The move affects Scotpharm (MNA) Limited and MSLNA Healthcare Limited, both of which are now listed on Companies House as being in administration.
The distinction between the holding companies and the operating subsidiaries is significant for the 420 employees, patients, and creditors linked to the businesses. BDO, the appointed administrator, has secured funding to allow continued trading, and suppliers are expected to be paid under normal terms. None of the operating subsidiaries have entered insolvency proceedings, which preserves operational continuity and the potential for a sale.
What is being sold?
Scotpharm acts as the holding company for Barrie Dear Limited, which runs 12 pharmacies under the Dears brand. MSLNA owns LP North Sixteen Limited, operating four pharmacies, and LP North Eighteen Limited, which runs another six. The group also includes two prescription-collection units.
James Stephen, Danny Dartnaill, and Benjamin Peterson of BDO were appointed as joint administrators. According to their statement, the operating subsidiaries remain outside the insolvency process, and the intention is to sell the pharmacies as going concerns. The Dears network is a well-known central Scotland operator with locations in Fife, Edinburgh, West Lothian, and Glasgow. A buyer would acquire the branch network, dispensing relationships, staff, and private clinical services, rather than just property and leases.
Financial strain
Scotpharm's latest filed group accounts, covering the 15 months to October 30, 2024, show turnover of £26.65 million. However, the balance sheet reveals significant strain: current assets of £9.33 million compared to £31.51 million in creditors due within one year, resulting in net current liabilities of £22.18 million and overall net liabilities of £2.46 million.
The income statement also showed a loss of £3.62 million for the period, driven by an operating loss of £1.71 million and £2.06 million in interest expenses. These figures predate the administration and should not be interpreted as current creditor-recovery estimates.
MSLNA's separate small-company balance sheet shows similar challenges. At October 30, 2024, it reported £9.31 million in investments and £1.68 million in debtors, but £11.68 million in creditors due within a year. Net current liabilities stood at £10.00 million, with total equity negative at £520,823. The filing was exempt from audit and did not include a profit-and-loss account.
Why normal trading matters
Keeping the operating subsidiaries outside administration preserves value for potential buyers. Pharmacies can continue dispensing, staff remain employed, and suppliers face no immediate disruption. It also gives BDO time to market the pharmacies as a whole or in smaller groups.
However, funding continuity does not guarantee a successful rescue. BDO has not disclosed a buyer, timetable, sale price, or expected recovery for holding-company creditors. Individual locations may attract different valuations, so a sale of all 22 branches as a single network is not assured, nor is protection for every job.
No listed acquirer has been named, leaving no public-equity trade to attach to the process. The next key evidence will be the administrators' proposals and any announced deal terms, including which branches are included, whether the operating companies transfer intact, and how much of the short-term liability gap the sale proceeds can cover.
